Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

Share Price Information for Angle (AGL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 13.75
Bid: 13.50
Ask: 14.00
Change: -0.25 (-1.79%)
Spread: 0.50 (3.704%)
Open: 14.00
High: 14.00
Low: 13.75
Prev. Close: 14.00
AGL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Geomerics - New Venture Co.

6 May 2005 07:00

Angle PLC06 May 2005 For Immediate Release 6 May 2005 ANGLE plc GEOMERICS: NEW VENTURE COMPANY ANGLE plc ("ANGLE"), the venture management and consulting company specialisingin the commercialisation of technology, is pleased to announce the launch of itslatest venture company, Geomerics Ltd ('Geomerics'). Geomerics has secured intellectual property in the field of geometric algebra.Geometric Algebra is a powerful new form of mathematics that vastly simplifiescomplex geometric calculations. Geometric Algebra has its origins in the ratheresoteric academic discipline of theoretical cosmology, but it has now beendeveloped for application in a wide variety of disparate commercial applicationssuch as computer graphics in computer games and electromagnetic modelling whichis used, amongst other things, for optimising the design of mobile phoneantennas and reducing the radar signature of ships and planes. One of the main differentiators between computer games is the speed and qualityof rendering of the graphics. With best-selling games generating severalhundred million dollars for their developers, the quest for better and fastergraphics engines is relentless. Geomerics' technology provides a step-changeimprovement over the competition, and is set to revolutionise the market.Overall the market for computer games is currently worth more than $30bn andgrowing rapidly, and the market for graphics within these games is worth over$600m per year. Current electromagnetic modelling techniques do not give the accuracy requiredin many applications, because the processing power required is prohibitive.Geomerics' technology has already been used to resolve complex electromagneticmodelling problems that rival systems have been unable to solve. Theelectromagnetic modelling market is worth in excess of $100m per year and thereis also considerable latent demand. This new approach in applying geometric algebra has been developed by a group offour leading academics from the University of Cambridge: Professor AnthonyLasenby (Professor of Astrophysics and Cosmology), Dr Mike Hobson (UniversityReader in Astrophysics), Dr Chris Doran (EPSRC Advanced Research Fellow) and DrJoan Lasenby (Lecturer in Engineering). Geomerics has also engaged ProfessorDavid Hestenes of Arizona State University (the original inventor of geometricalgebra) and Professor Alyn Rockwood of Colorado School of Mines (a geometricalgebra and computer graphics expert) in an advisory capacity. In accordance with ANGLE's Progeny(R) process for creating new ventures, ANGLE'splan is to build a strong commercial offering in each of the key marketssequentially, seeking a return on its investment in the medium term.Simultaneously, development work will continue on the geometric algebraplatform. ANGLE expects to spend up to £500,000 in the Progeny(R) venture, whichis presently wholly owned by ANGLE. Commenting on the collaboration with ANGLE, Professor Lasenby said: 'We have been developing the mathematics and technology behind Geomerics for anumber of years, and now is the perfect time to apply it to commercialapplications. We are delighted that ANGLE will be commercialising ourtechnology.' ANGLE's Chief Executive Andrew Newland said: 'Computer graphics and electromagnetic modelling are large, growing markets.Geomerics' technology is truly leading-edge and we believe it will revolutionisea wide range of fields. We are delighted to be working with such a high calibreof academic inventors.' For further information: ANGLE plcAndrew Newland, Chief Executive 01483 295830Stephen Bence, Associate Director - Ventures UK 01223 472745 Buchanan Communications 020 7466 5000Richard Darby, Suzanne Brocks Notes to Editors Founded in 1994, ANGLE is an international venture management and consultingcompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
10th Jan 20227:00 amRNSInsight into drug resistance in NSCLC
22nd Dec 20216:29 pmRNSIssue of Equity
1st Dec 20216:11 pmRNSIssue of Equity
1st Dec 20217:00 amRNSParsortix in RNA analysis of CTCs as tool in NSCLC
26th Nov 20215:33 pmRNSIssue of Equity
17th Nov 202110:32 amRNSIssue of Equity
15th Nov 20217:00 amRNSIssue of LTIP Options and Share Options
15th Nov 20217:00 amRNSAppointment of Chief Medical Officer
12th Nov 20215:51 pmRNSIssue of Equity
12th Nov 20217:00 amRNSParticipation at Jefferies healthcare conference
11th Nov 20217:00 amRNSParsortix system showcased at NCRI Festival
10th Nov 20215:40 pmRNSIssue of Equity
2nd Nov 20217:00 amRNSChange of Adviser
21st Oct 20215:25 pmRNSIssue of Equity
15th Oct 20215:45 pmRNSIssue of Equity
30th Sep 20214:02 pmRNSIssue of Equity
30th Sep 20217:00 amRNSInterim Results
27th Sep 20217:00 amRNSParsortix demonstrates ability to isolate CTCs
22nd Sep 20217:00 amRNSStudy shows use of Parsortix to assess PD-L1
20th Sep 20217:00 amRNSParsortix enables gene expression analysis in mPCa
7th Sep 20217:00 amRNSNotice of Interim Results and Webcast
24th Aug 20217:00 amRNSDirector/PDMR Shareholding
9th Aug 20217:00 amRNSStudy highlights superior performance of Parsortix
6th Aug 20211:17 pmRNSIssue of Equity
3rd Aug 20213:13 pmRNSIssue of Equity
28th Jul 20217:00 amRNSContract secured for bespoke assay development
9th Jul 20217:00 amRNSHarvesting CTCs from brain metastasis patients
7th Jul 20216:34 pmRNSDirector/PDMR Shareholding
2nd Jul 202110:45 amRNSIssue of Equity
30th Jun 20213:44 pmRNSResult of AGM
25th Jun 20217:00 amRNSResult of Accelerated Bookbuild
24th Jun 20216:28 pmRNSAccelerated bookbuild to raise up to £20m
18th Jun 202111:42 amRNSAnnual General Meeting update
18th Jun 20217:00 amRNSctDNA and CTCs have differences in EGFR mutations
4th Jun 20217:00 amRNSUpdate on submission for FDA clearance
1st Jun 20217:00 amRNSPotential to prevent breast cancer relapse
20th May 20217:00 amRNSParsortix demonstrates oesophageal cancer utility
19th May 20214:37 pmRNSExercise of options and total voting rights
11th May 20217:00 amRNSParsortix study uncovers targets in TNBC patients
30th Apr 202111:22 amRNSExercise of options and total voting rights
29th Apr 20217:00 amRNSPreliminary Results
26th Apr 20217:00 amRNSOvarian cancer study patient enrolment completed
19th Apr 20212:05 pmRNSSecond Price Monitoring Extn
19th Apr 20212:00 pmRNSPrice Monitoring Extension
19th Apr 202111:05 amRNSSecond Price Monitoring Extn
19th Apr 202111:00 amRNSPrice Monitoring Extension
16th Apr 20217:00 amRNSFirst large-scale pharma services contract secured
15th Apr 20214:10 pmRNSNotice of Preliminary Results and Webcast
12th Apr 20217:00 amRNSANGLE's Parsortix system showcased at AACR 2021
30th Mar 20217:00 amRNSGlobal launch of clinical services laboratories

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.